ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Revenue of ORIC Pharmaceuticals, Inc. (ORIC)
Revenue in 2023 (TTM): $
According to ORIC Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of ORIC Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-1,032,000 | $-109,748,000 | $-100,697,000 | $-100,697,000 |
| 2022 | $ | $-966,000 | $-91,767,000 | $-89,122,000 | $-91,477,000 |
| 2021 | $ | $-897,000 | $-77,974,000 | $-78,715,000 | $-77,677,000 |
| 2020 | $ | $-970,000 | $-74,186,000 | $-73,703,000 | $-97,270,000 |
| 2019 | $ | $-1,000,000 | $-27,541,000 | $-26,883,000 | $-25,486,000 |
| 2018 | $ | $-900,000 | $-20,463,000 | $-21,363,000 | $-21,363,000 |
| 2017 | $ | $-900,000 | $-21,129,000 | $-22,029,000 | $-22,029,000 |